Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18631832 | 0.91 | MAPT (0.68) | MAPTKMT2AKDM4EGLAKDM1A | |
| SCHEMBL18631825 | 0.77 | KMT2A (0.48) | MAPTKMT2AKDM4EGLAMAOA | |
| SCHEMBL676532 | 0.76 | MAPT (0.50) | MAPTKMT2AKDM4EGLAKDM1A | |
| SCHEMBL4898172 | 0.75 | KDM4E (0.70) | MAPTKMT2AKDM4EGLAKDM1A | |
| SCHEMBL30003990 | 0.75 | KDM4E (0.70) | MAPTKMT2AKDM4EGLAKDM1A | |
| SCHEMBL28627795 | 0.74 | KDM4E (0.63) | MAPTKMT2AKDM4EGLAKDM1A | |
| SCHEMBL455804 | 0.74 | KDM4E (1.00) | MAPTKMT2AKDM4EGLAKDM1A | |
| SCHEMBL1052575 | 0.73 | MAPT (0.52) | MAPTKMT2AKDM4EGLAKDM1A | |
| SCHEMBL5992678 | 0.72 | KDM4E (0.50) | MAPTKMT2AKDM4EGLATSHR | |
| SCHEMBL27976243 | 0.72 | MAPT (0.50) | MAPTKMT2AKDM4EGLAKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377784-B2 | Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith | WAKE FOREST UNIVERSITY (US) | 2019-08-13 | — | — | US | disclosed |
| US-10023599-B2 | Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith | WAKE FOREST UNIVERSITY (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023599-B2 | Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith | WAKE FOREST UNIVERSITY (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170081351-A1 | Design, Synthesis, and Biological Activity of Platinum-benz[c]acridine Hybrid Agents and Methods Associated Therewith | WAKE FOREST UNIVERSITY | 2017-03-23 | — | — | US | disclosed |
| US-20170081351-A1 | Design, Synthesis, and Biological Activity of Platinum-benz[c]acridine Hybrid Agents and Methods Associated Therewith | WAKE FOREST UNIVERSITY | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023599-B2 | Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith | ACR, TP53, MCL1 | MAPT 4258/4885KMT2A 3861/4885KDM4E 4196/4885 |
| US-10377784-B2 | Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith | ACR, TP53, BAD | MAPT 4127/4885KMT2A 3810/4885KDM4E 4210/4885 |
| US-20170081351-A1 | Design, Synthesis, and Biological Activity of Platinum-benz[c]acridine Hybrid Agents and Methods Associated Therewith | ACR, TP53, MCL1 | MAPT 4258/4885KMT2A 3861/4885KDM4E 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.